Prescribing patterns amongst UK dermatologists for the treatment of alopecia areata, female pattern hair loss, and frontal fibrosing alopecia

Abstract Background Therapeutic management of hair loss is frequently complicated by a lack of high‐quality evidence and reliant on the use of unlicensed therapies. Treatment decision‐making is predominantly based on expert opinion, local availability, personal experience, and cost, which make informed choices challenging for clinicians and patients in this area. Objectives The aims were to determine prescribing patterns amongst UK Dermatologists with a special interest in hair disorders, when treating mild‐moderate alopecia areata (AA), severe AA (including alopecia totalis/alopecia universalis), female pattern hair loss (FPHL) and frontal fibrosing alopecia (FFA). Methods Consultant members of the British Hair and Nail society, a special interest group affiliated to the British Association of Dermatologists, were invited to participate from across the United Kingdom. Participants were questioned on their current prescribing patterns in both NHS and private practice, were asked to rank their first‐to‐fifth line treatments for each condition and highlight the treatment they perceive as most effective for each disorder. Results Twenty‐six Consultant Dermatologists completed the questionnaire, from twenty‐three institutions. For treatment of mild‐moderate AA, topical corticosteroids were used first line amongst 65% ( n = 17) of respondents, and 82% ( n = 23) reported that intralesional corticosteroids were the most effective treatment. For severe AA, oral corticosteroids were used first line amongst 38% ( n = 10) of respondents, and 25% ( n = 8) reported that oral corticosteroids were the most effective treatment. For FPHL, topical minoxidil was used first line amongst 84% ( n = 25) of respondents, and 42% ( n = 10) reported that oral minoxidil was the most effective treatment. For FFA, topical corticosteroids were used first line amongst 62% ( n = 16) of respondents, and 37% ( n = 14) reported that hydroxychloroquine was the most effective treatment. Conclusions This study reports real‐world prescribing practices amongst dermatologists treating common hair loss conditions. These results aim to support clinicians with decision making for managing hair loss conditions.

Authors

Institutions

Publication Details

Journal
JEADV Clinical Practice
Published
2024-10-23
DOI
https://doi.org/10.1002/jvc2.495
Citations
1
Primary Topic
Hair Growth and Disorders
Type
article
Field-Weighted Citation Impact
0.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prescribing patterns amongst UK dermatologists for the treatment of alopecia areata, female pattern hair loss, and frontal fibrosing alopecia

Leila Asfour, Anita Takwale, Donna M. Cummins, Nekma Meah et al.
1 citations
JEADV Clinical Practice
Hair Growth and Disorders
0.54
article

Prescribing patterns amongst UK dermatologists for the treatment of alopecia areata, female pattern hair loss, and frontal fibrosing alopecia

Leila Asfour, Anita Takwale, Donna M. Cummins, Nekma Meah, Alyson Bryden, Sharon L. Wong, Thomas Harries, S. Karanovic, John Frewen, Nicola Clayton, Dalia Saidely Alsaadi, G. Hale, Yusur Al‐Nuaimi, Paul Farrant, Simon Holmes, Matthew Harries, Ruth Ellen Jones, Nicola Salmon, Martin Wade, David Fairhurst, Caroline Champagne, Sharon Belmo, Manjit Kaur, Shirin Zaheri, Megan Mowbray, Nicola Cooke, Archana Rao, Nasim Rouhani
article en
1 citations

Abstract

Abstract Background Therapeutic management of hair loss is frequently complicated by a lack of high‐quality evidence and reliant on the use of unlicensed therapies. Treatment decision‐making is predominantly based on expert opinion, local availability, personal experience, and cost, which make informed choices challenging for clinicians and patients in this area. Objectives The aims were to determine prescribing patterns amongst UK Dermatologists with a special interest in hair disorders, when treating mild‐moderate alopecia areata (AA), severe AA (including alopecia totalis/alopecia universalis), female pattern hair loss (FPHL) and frontal fibrosing alopecia (FFA). Methods Consultant members of the British Hair and Nail society, a special interest group affiliated to the British Association of Dermatologists, were invited to participate from across the United Kingdom. Participants were questioned on their current prescribing patterns in both NHS and private practice, were asked to rank their first‐to‐fifth line treatments for each condition and highlight the treatment they perceive as most effective for each disorder. Results Twenty‐six Consultant Dermatologists completed the questionnaire, from twenty‐three institutions. For treatment of mild‐moderate AA, topical corticosteroids were used first line amongst 65% ( n = 17) of respondents, and 82% ( n = 23) reported that intralesional corticosteroids were the most effective treatment. For severe AA, oral corticosteroids were used first line amongst 38% ( n = 10) of respondents, and 25% ( n = 8) reported that oral corticosteroids were the most effective treatment. For FPHL, topical minoxidil was used first line amongst 84% ( n = 25) of respondents, and 42% ( n = 10) reported that oral minoxidil was the most effective treatment. For FFA, topical corticosteroids were used first line amongst 62% ( n = 16) of respondents, and 37% ( n = 14) reported that hydroxychloroquine was the most effective treatment. Conclusions This study reports real‐world prescribing practices amongst dermatologists treating common hair loss conditions. These results aim to support clinicians with decision making for managing hair loss conditions.

JEADV Clinical PracticeVol. 4(1)
University Hospitals Birmingham NHS Foundation Trust (GB), Imperial College Healthcare NHS Trust (GB), Royal Devon & Exeter NHS Foundation Trust (GB), Wrexham Maelor Hospital (GB), Manchester Academic Health Science Centre (GB), NHS Greater Glasgow and Clyde (GB), Glasgow Royal Infirmary (GB), St Helens and Knowsley Teaching Hospitals NHS Trust (GB), London Clinic (GB), Churchill Hospital (GB), Watford General Hospital (GB), Kingston Hospital NHS Trust (GB), Gloucestershire Hospitals NHS Foundation Trust (GB), Ninewells Hospital (GB), Edinburgh Royal Infirmary (GB), Queen Margaret Hospital (GB), University of Manchester (GB), Salford Royal Hospital (GB), British Association of Dermatologists (GB), Central Middlesex Hospital (GB), Chelsea and Westminster Hospital (GB), University Hospitals Sussex NHS Foundation Trust (GB), Queen Elizabeth University Hospital (GB), NIHR Manchester Biomedical Research Centre (GB), Newcastle University (GB)
National Institute for Health and Care Research, Manchester Biomedical Research Centre
Openalex Percentile: Top 30%
Hair Growth and Disorders
0.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.